<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04865770</url>
  </required_header>
  <id_info>
    <org_study_id>NN9535-4662</org_study_id>
    <secondary_id>U1111-1248-7912</secondary_id>
    <secondary_id>2020-000828-19</secondary_id>
    <nct_id>NCT04865770</nct_id>
  </id_info>
  <brief_title>A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)</brief_title>
  <acronym>REMODEL</acronym>
  <official_title>Renal Mode of Action of Semaglutide in Patients With Type 2 Diabetes and Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are doing this study to learn more about how semaglutide may help fight chronic kidney&#xD;
      disease in people with type 2 diabetes. We are doing this by looking into how semaglutide&#xD;
      works in the kidneys.&#xD;
&#xD;
      Participants will either get semaglutide or placebo (a 'dummy' medicine) - which treatment&#xD;
      participants get is decided by chance.&#xD;
&#xD;
      Semaglutide is a medicine doctors can prescribe in some countries for the treatment of type 2&#xD;
      diabetes.&#xD;
&#xD;
      Participants will get the study medicine in a pen. Participants will use the pen to inject&#xD;
      the medicine into the skin once a week.&#xD;
&#xD;
      The study will last for about 1 year. Participants will have 11 visits to the clinic, and 2&#xD;
      phone visits. Some of the visits could be in different locations.&#xD;
&#xD;
      Study staff will take blood samples at most of these visits. At 9 visits, participants will&#xD;
      be asked to bring a sample of their first morning urine. At 4 of the visits participants will&#xD;
      have to bring urine that they have collected over the last 24 hours.&#xD;
&#xD;
      The study includes magnetic resonance imaging (MRI) scans of participants' kidneys which is a&#xD;
      test that shows a detailed picture of organs and other parts inside the body. The scan will&#xD;
      last for 30 minutes, and is free of radiation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2021</start_date>
  <completion_date type="Anticipated">July 19, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 8, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Sponsor staff involved in the clinical trial is masked according to company standard procedures.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in kidney oxygenation (cortex), BOLD (blood oxygenation-level dependent) MRI ( magnetic resonance imaging )</measure>
    <time_frame>From baseline (week 0) to end of treatment (week 52)</time_frame>
    <description>ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in kidney oxygenation (medulla), BOLD MRI(R2)</measure>
    <time_frame>From baseline (week 0) to end of treatment (week 52)</time_frame>
    <description>ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in global kidney perfusion (MRI)</measure>
    <time_frame>From baseline (week 0) to end of treatment (week 52)</time_frame>
    <description>ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in kidney inflammation (cortex), T1 mapping (MRI)</measure>
    <time_frame>From baseline (week 0) to end of treatment (week 52)</time_frame>
    <description>ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in kidney inflammation (medulla), T1 mapping (MRI)</measure>
    <time_frame>From baseline (week 0) to end of treatment (week 52)</time_frame>
    <description>ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in gene expression assessed by single nucleus RNA sequencing (kidney biopsy)</measure>
    <time_frame>From baseline (week 0) to end of treatment (week 52)</time_frame>
    <description>log2 fold-change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glomerular basement membrane width (kidney biopsy)</measure>
    <time_frame>From baseline (week 0) to end of treatment (week 52)</time_frame>
    <description>nm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ADC (apparent diffusion coefficient) (cortex) (MRI)</measure>
    <time_frame>From baseline (week 0) to end of treatment (week 52)</time_frame>
    <description>ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ADC (medulla) (MRI)</measure>
    <time_frame>From baseline (week 0) to end of treatment (week 52</time_frame>
    <description>ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean RARI (renal artery resistive index ) (MRI)</measure>
    <time_frame>From baseline (week 0) to end of treatment (week 52)</time_frame>
    <description>ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean arterial flow (MRI)</measure>
    <time_frame>From baseline (week 0) to end of treatment (week 52)</time_frame>
    <description>ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in natriuresis (urinary sodium excretion) (urinalysis)</measure>
    <time_frame>From baseline (week 0) to end of treatment (week 52)</time_frame>
    <description>mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in albumin excretion rate (urinalysis)</measure>
    <time_frame>From baseline (week 0) to end of treatment (week 52)</time_frame>
    <description>mg/24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in kidney function (creatinine clearance) (urinalysis</measure>
    <time_frame>From baseline (week 0) to end of treatment (week 52</time_frame>
    <description>ml/min/1.73 m^2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Semaglutide 1.0 mg OW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once-weekly (OW) Semaglutide administered subcutaneously (s.c., under the skin).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Semaglutide) 1.0 mg OW</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once-weekly (OW) placebo (Semaglutide) administered subcutaneously (s.c., under the skin).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide</intervention_name>
    <description>Semaglutide given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.</description>
    <arm_group_label>Semaglutide 1.0 mg OW</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Semaglutide)</intervention_name>
    <description>Placebo (Semaglutide) given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.</description>
    <arm_group_label>Placebo (Semaglutide) 1.0 mg OW</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female.&#xD;
&#xD;
          -  Age above or equal to 18 years at the time of signing informed consent.&#xD;
&#xD;
          -  Diagnosed with T2D (type 2 diabetes) greater than or equal to 180 days prior to the&#xD;
             day of screening.&#xD;
&#xD;
          -  HbA1c (glycated haemoglobin) below or equal to 9.0 percent (below or equal to 75&#xD;
             mmol/mol).&#xD;
&#xD;
          -  Serum creatinine-based eGFR greater than or equal to 40 and below or equal to 75&#xD;
             mL/min/1.73 m^2 (CKD-EPI).&#xD;
&#xD;
          -  UACR ( Urinary albumin-to-creatinine ratio ) greater than or equal to 30 and below&#xD;
             5000 mg/g.&#xD;
&#xD;
          -  Treatment with maximum labelled or tolerated dose of a renin-angiotensin-aldosterone&#xD;
             system (RAAS) blocking agent including an angiotensin converting enzyme (ACE)&#xD;
             inhibitor or angiotensin II receptor blocker (ARB). Treatment dose must be stable for&#xD;
             at least 28 days prior to screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any glucagon-like peptide 1 receptor agonist (GLP-1 RA) within 30 days prior to&#xD;
             screening.&#xD;
&#xD;
          -  A prior solid organ transplant or awaiting solid organ transplant.&#xD;
&#xD;
          -  Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or&#xD;
             transient ischaemic attack within 180 days prior to the day of screening.&#xD;
&#xD;
          -  Presence or history of malignant neoplasms (other than basal or squamous cell skin&#xD;
             cancer, in situ carcinomas of the cervix, or in situ prostate cancer) within 5 years&#xD;
             prior to the day of screening.&#xD;
&#xD;
          -  Congenital or hereditary kidney diseases including polycystic kidney disease,&#xD;
             autoimmune kidney diseases including glomerulonephritis or congenital urinary tract&#xD;
             malformations.&#xD;
&#xD;
          -  Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by&#xD;
             a fundus examination performed within the past 90 days prior to screening or in the&#xD;
             period between screening and Visit 2. Pharmacological pupil-dilation is a requirement&#xD;
             unless using a digital fundus photography camera specified for non-dilated&#xD;
             examination.&#xD;
&#xD;
          -  Treatment with systemic anti-inflammatory or immunosuppressant drugs within 90 days&#xD;
             prior to screening. Stable treatment with acetylsalicylic acid for prevention of&#xD;
             cardiovascular events and occasional use of propionic acid derivatives drugs (e.g.&#xD;
             ibuprofen) is allowed.&#xD;
&#xD;
          -  Any contraindication for MRI according to standard checklist used in clinical routine,&#xD;
             including claustrophobia or metallic foreign bodies, metallic implants, internal&#xD;
             electrical devices, or permanent makeup/tattoos that cannot be declared MR compatible.&#xD;
&#xD;
          -  Combination use of an ACE (angiotensin-converting enzyme) inhibitor and an ARB&#xD;
             (angiotensin II receptor blockers).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Transparency (Dept.1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>San Dimas</city>
        <state>California</state>
        <zip>91773</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>AMIENS cedex 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bois-Guillaume</city>
        <zip>76230</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Grenoble - CÃ©dex 09</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Radom</city>
        <zip>26-600</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 26, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

